Current stock page

Catalysts

MIRM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

MIRMMirum Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$93.99+$0.66 (+0.71%)

Latest quote

  • Momentum
    54
  • Value
    57
  • Quality
    52
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 53/100

Momentum 54/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 33.90%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 54/100AIQ Edge 5/10 In Line With Peers
Beat rate
38%
3 of 8 reported periods
Average surprise
-484.5%
Across covered historical reports
Latest result
-78.7%
Nov 3, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2026—-$0.49-$0.87-78.7%$178.08M$185.72M
Aug 5, 2026—-$0.74-$1.06-42.8%$166.33M$176.2M
May 6, 2026—-$0.40-$13.43-3257.5%$148.21M$159.9M
Feb 25, 2026—$0.02-$0.11-650.0%$142.5M$148.93M
Nov 4, 2025—-$0.10$0.05+150.0%$140.88M$133.01M
Aug 6, 2025—-$0.31-$0.12+61.3%$130.11M$127.79M
May 7, 2025—-$0.39-$0.30+23.1%$98.4M$111.59M
Feb 26, 2025—-$0.27-$0.49-81.5%$96.64M$99.41M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
14
Buy
12-month analyst target
$156.89
+66.92% versus current price
Based on 14 analyst observations. Targets are estimates, not predictions.
Low target
$130.00
+38.31% vs latest price
Average target
$156.89
+66.92% vs latest price
High target
$202.00
+114.92% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate-$0.62

Current analyst expectation for the upcoming report.

Revenue estimate$194.47M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score54

Where event reaction would show up first.

AIQ score53/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
14
Average target
$156.89
Target upside
66.92%
Target range
$130.00 - $202.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Nov 4, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call November 3, 2026 4:30 PM ESTCompany ParticipantsAndrew McKibben - Senior Vice President, Strategic...

zacks.com · Nov 3, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -64.15% and +5.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

zacks.com · Oct 27, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com · Oct 21, 2026

Mirum Pharmaceuticals (MIRM) Receives FDA Orphan Drug Designation for Brelovitug in Hepatitis Delta

On October 21, 2026, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) announced that its investigational treatment brelovitug has been granted orphan drug designation b

gurufocus.com · Oct 21, 2026

MIRM Maintains Rating by TD Cowen -- Price Target Raised to $145

Mirum Pharmaceuticals (MIRM) Analyst Rating Update On October 13, 2026, Mirum Pharmaceuticals (MIRM) received a "Buy" rating from TD Cowen, with analyst Jose

Open full news and sentiment

MIRM Catalysts FAQ

What are the next catalysts for MIRM stock?

MIRM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move MIRM stock?

Upcoming events that could move MIRM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could MIRM's next earnings report affect the stock?

MIRM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive MIRM stock higher?

MIRM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt MIRM stock?

MIRM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.